By Veronika Gulyas
BUDAPEST--Hungary-based central European pharmaceutical company
Richter Gedeon Nyrt. (RICHTER.BU) said Tuesday that it has signed a
license and distribution agreement with Bayer HealthCare, part of
Germany's Bayer AG (BAYRY).
The deal involves the sales of Bayer's low-dose contraceptive
drug under the trademark Lisvy in the European Union and other
European countries, as well as parts of Latin America.
Under the terms of the agreement, Richter will make an initial
payment upon signing the contract followed by further milestone
payments.
Moreover, further sales-related royalties will be payable to
Bayer subsequent to the launch of the product.
Richter will also be conducting and funding a post-authorization
safety study in line with European Medicines Agency
regulations.
The agreement widens the scope of Richter's branded female
health-care franchise worldwide, one of the company's key segments,
said Chief Executive Erik Bogsch.
Write to Veronika Gulyas at veronika.gulyas@wsj.com; Twitter:
@VeronikaGulyas1
Subscribe to WSJ: http://online.wsj.com?mod=djnwires